A small molecule drug designed to inhibit the neonatal Fc receptor (FcRn) via oral administration, aiming to reduce pathogenic IgG levels in autoimmune diseases.

An integrated drug discovery platform that supports hit finding, lead optimization, and candidate selection across a range of molecular weights for oral drug development.